Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod In EU

By Zacks Investment ResearchStock MarketsNov 17, 2017 03:16AM ET

www.investing.com/analysis/glaxos-triple-therapy-copd-inhaler-gets-marketing-nod-in-eu-200266385

Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod In EU

By Zacks Investment Research | Nov 17, 2017 03:16AM ET

Saved. See Saved Items.

This article has already been saved in your Saved Items

JNJ

-0.18%

Add to/Remove from Watchlist

INVA

+0.23%

Add to/Remove from Watchlist

GSK

+0.99%

Add to/Remove from Watchlist

TBPH

+6.81%

Add to/Remove from Watchlist

GlaxoSmithKline plc (NYSE:GSK) and partner Innoviva, Inc. (NASDAQ:INVA) announced that their triple combination therapy was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with chronic obstructive pulmonary disease (COPD).

The once-daily single inhaler triple therapy will be marketed by the trade name of Trelegy Ellipta. It is approved for the treatment of moderate-to-severe COPD in patients who are already being treated with a combination of inhaled corticosteroid (ICS) and a long-acting beta2-adrenergic agonist (LABA) but require additional bronchodilation.

Trelegy Ellipta was approved in the United States in September this year. The EU approval was expected. This is because the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) had granted a positive opinion recommending marketing approval of Trelegy Ellipta in September.

Trelegy Ellipta, a combination of fluticasone furoate – an ICS, umeclidinium – a long-acting muscarinic antagonist (LAMA) and vilanterol – a LABA therapy, will provide patients with a convenient dosing option by removing the need for multiple inhalers. The product is expected to bring in blockbuster sales. Trelegy Ellipta will be delivered in Glaxo’s Ellipta dry powder inhaler.

Glaxo’s shares have declined 8.6% this year so far, underperforming the 14.7% increase witnessed by the industry.

Please note that shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) were up more than 6% on Thursday as the biotech has an economic interest on the royalties that Glaxo will pay to Innoviva on global sales of Trelegy Ellipta.

Glaxo has a Zacks Rank #3 (Hold).

A better-ranked stock in the large-cap pharma sector is Johnson & Johnson (NYSE:JNJ) with a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Shares of J&J are up 20.5% so far this year while earnings estimates for 2018 have gone up by almost 1% over the past 30 days.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>

Johnson & Johnson (JNJ): Free Stock Analysis Report

GlaxoSmithKline PLC (GSK): Free Stock Analysis Report

Innoviva, Inc. (INVA): Free Stock Analysis Report

Theravance Biopharma, Inc. (TBPH): Free Stock Analysis Report

Original post

Zacks Investment Research

Zoom Stock: Leading the Video Market After Skype’s Exit By Gabriel Osorio-Mazzilli - Mar 05, 2025

As the digital economy starts to go online across businesses and the world, investors have to be aware of the companies and services that will be at the forefront of this...

Dow's Resilience Tested by Tariff Actions and Economic Signals By Zain Vawda - Mar 05, 2025

Wall Street Indexes remain under pressure today but have held above the lows we saw on Tuesday as the Trump administration tariffs came into force. The announcement of tariffs on...

3 Safe-Haven Stocks to Buy Amidst a Global Trade War By Jesse Cohen - Mar 05, 2025 5

These stocks provide a compelling case as safe-haven stocks in the face of an escalating trade war. Each company operates within sectors that are relatively resilient to economic...

Add a Comment

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:

Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
Only English comments will be allowed.
Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I have read Investing.com's comments guidelines and agree to the terms described.

I Agree

Write your thoughts here

Are you sure you want to delete this chart?

Delete Cancel

Post

Post also to:

Replace the attached chart with a new chart ?

Replace Cancel

1000

Comment Guidelines

Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.

Please wait a minute before you try to comment again.

Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.

<div id="comment">
				<div class="comment js-comment" data-comment-id="{commentID}" id="comment-{commentID}" data-user-id="">
    <div class="mainComment js-content">
       <div class="commentInnerWrapper">
        <a href="{userLink}" class="js-user-link"><img src="{userImage}" width="33" height="33" alt="{usernameAlt}" class="img" onerror="this.src='https://i-invdn-com.investing.com/defaultUserMaleTmp.png';"></a><div class="commentBody">
                					<span class="commentUsername">
                    	<a href="{userLink}" class="js-user-link js-user-name">{username}</a>
					</span>
                                <span class="js-date" comment-date="{dateFormat}" comment-date-formatted="{dateFormatted}" title="{dateTitle}">Just Now</span>
                <div class="commentDropDown js-commentDropDownWrapper " data-user-id="" data-cid="{commentID}">
	<a href="javascript:void(0);" class="threeDotsIconSmall js-thinDropdownArrow"></a>
	<div class="tooltipPopup commentActionsPop noHeader js-commentDropDownOptions displayNone">
		<div class="addRow js-option share">
			<a href="javascript:void(0);" class="js-commentSharePopup" data-cid="{commentID}" data-curl="{commentLink}"><span class="smallShareIcon middle"></span>Share</a>
		</div>

<div class="js-option addRow follow">
            <div class="js-follow-post-button" data-reg_ep="follow comment">
                <span class="alertfollowIcon middle"></span>Follow this post            </div>
            <div class="js-unfollow-post-button displayNoneImp">
                <span class="alertUnfollowIcon middle"></span>Unfollow this post            </div>
        </div>

<div class="addRow js-option save"  data-reg_ep="save comment">
		<a href="javascript:void(0);" class="js-save-item-btn" data-item-type="comments" data-item-id="{commentID}">
			<i class="saveItemBigIcon middle"></i>
			Save		</a>
	</div>
	<div class="addRow saveItemsConfirmation noHover displayNone js-saveItemResult">
		
<div class="content js-saveItemSuccess displayNone">
	<span class="mediumGreenSuccessIcon"></span><span>Saved. See <a href="/members-admin/saved-items" target="_blank">Saved Items</a>.</span>
	<a href="javascript:void(0);" class="bugCloseIcon js-close"></a>
</div>
<div class="content js-saveItemAlreadySaved saveItemAlreadySaved displayNoneImp">
	<span>This comment has already been saved in your <a href="/members-admin/saved-items" target="_blank">Saved Items</a></span>
	<a href="javascript:void(0);" class="bugCloseIcon js-close"></a>
</div>
	</div>

<div class="addRow shareButtons js-sharePopup displayNone">
			<div class="js-shareComment"><span class="js-shareCommentSpan"></span></div>
		</div>
	</div>
</div>
                 <div class="commentAuthor js-comment-by-author"><span class="commentAuthorIcon"></span>Author's response</div>             </div>
		<div id="commentText-{commentID}" class="js-text-wrapper commentText withImage">
							<div id="commentBigChart{commentID}" class="commentBigChart js-comment-chart" onclick="openViewChartPopup('{commentID}')">
					<img src="https://d1-invdn-com.investing.com/comments_images/{commentImage}" alt="{commentAlt}">
					<i class="newMagnifyChartIcon"></i>
				</div>
						<span class="js-text">{commentContent}</span>
			<div class="clear"></div>
							<div class="commentButtons js-not-master-user">
					<a href="javascript:void(0)" class="reply js-reply-btn" data-real-parent-id="{commentID}" data-to-user-name="{username}" data-to-user-id="">Reply</a>
					<div class="inlineblock likeDislikeBox js-like-dislike-box" data-item-id="{commentID}">
	<input class="js-like-checkbox" type="checkbox" name="option" value="Yes" id="like_{commentID}">
	<label for="like_{commentID}" class="like" title="I agree"></label>
	<span class="numOfLikes js-like-count lighterGrayFont">0</span>
	<input class="js-dislike-checkbox" type="checkbox" name="option" value="No" id="dislike_{commentID}">
	<label for="dislike_{commentID}" class="dislike" title="I disagree"></label>
	<span class="numOfDislikes js-dislike-count lighterGrayFont">0</span>
</div>

<div class="reportComment js-flag float_lang_base_2">
                            <a href="javascript:void(0);" id="commentFlag_{commentID}">
                                <span class="reportCommentIcon middle"></span><span class="inlineblock middle">Report</span>
                            </a>
                        </div>
                    				</div>
					</div>
	   </div>
	</div>
	</div>			</div>
			<div id="reply">
				
    <div class="commentReply js-comment js-comment-reply" data-comment-id="{commentID}" id="comment-{commentID}" data-user-id="">
		<div class="commentInnerWrapper"><a href="{userLink}" class="js-user-link"><img src="{userImage}" width="33" height="33" alt="{usernameAlt}" class="img" onerror="this.src='https://i-invdn-com.investing.com/defaultUserMaleTmp.png';"></a><div class="commentBody js-content">
            				<span class="commentUsername">
					<a href="{userLink}" class="commentUsername js-user-link js-user-name" onMouseOver="">{username}</a>
				</span>
                        <span class="js-date" comment-date="{dateFormat}" comment-date-formatted="{dateFormatted}" title="{dateTitle}">Just Now</span>
			 <div class="commentAuthor js-comment-by-author"><span class="commentAuthorIcon"></span>Author's response</div> 			<div class="commentDropDown js-commentDropDownWrapper " data-user-id="" data-cid="{commentID}">
	<a href="javascript:void(0);" class="threeDotsIconSmall js-thinDropdownArrow"></a>
	<div class="tooltipPopup commentActionsPop noHeader js-commentDropDownOptions displayNone">
		<div class="addRow js-option share">
			<a href="javascript:void(0);" class="js-commentSharePopup" data-cid="{commentID}" data-curl="{commentLink}"><span class="smallShareIcon middle"></span>Share</a>
		</div>

</div>
		<div id="commentText-{commentID}" class="js-text-wrapper commentText withImage">
							<div id="commentBigChart{commentID}" class="replyBigChart displayNone js-comment-chart">
					<img src="https://d1-invdn-com.investing.com/comments_images/{commentImage}" alt="{commentAlt}">
					<i class="newMagnifyChartIcon"></i>
				</div>
				<span id="commentSmallChart{commentID}" class="commentSmallChart pointer js-comment-chart" onclick="openViewChartPopup('{commentID}')">
                    <img src="https://d1-invdn-com.investing.com/comments_images/{commentImageSmall}" width="116" height="52" alt="{commentAlt}">
                    <span class="chartMagnifyOverlay displayNone"></span>
                    <span class="searchGlassIcon chartMagnify displayNone"></span>
                </span>
						<span class="js-text">{commentContent}</span>
			<div class="clear"></div>
							<div class="commentButtons js-not-master-user">
					<a href="javascript:void(0)" class="reply js-reply-btn" data-real-parent-id="{commentID}" data-to-user-name="{username}" data-to-user-id="">Reply</a>
					<div class="inlineblock likeDislikeBox js-like-dislike-box" data-item-id="{commentID}">
	<input class="js-like-checkbox" type="checkbox" name="option" value="Yes" id="like_{commentID}">
	<label for="like_{commentID}" class="like" title="I agree"></label>
	<span class="numOfLikes js-like-count lighterGrayFont">0</span>
	<input class="js-dislike-checkbox" type="checkbox" name="option" value="No" id="dislike_{commentID}">
	<label for="dislike_{commentID}" class="dislike" title="I disagree"></label>
	<span class="numOfDislikes js-dislike-count lighterGrayFont">0</span>
</div>

Are you sure you want to delete this chart?

Delete Cancel

Post

Replace the attached chart with a new chart ?

Replace Cancel

1000

Comment Guidelines

Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.

Please wait a minute before you try to comment again.

I feel that this comment is:

Spam

Offensive

Thank You!

Your report has been sent to our moderators for review

Central Banks

Interest Rates

Next Meeting

FED

4.50%

Mar 19, 2025

ECB

2.90%

Mar 06, 2025

BOE

4.50%

Mar 20, 2025

SNB

0.50%

Mar 20, 2025

RBA

4.10%

Apr 01, 2025

BOC

3.00%

Mar 12, 2025

RBNZ

3.75%

Apr 09, 2025

BOJ

0.50%

Mar 19, 2025

CBR

21.00%

Mar 21, 2025

RBI

6.25%

Mar 10, 2025

PBOC

3.10%

BCB

13.25%

Mar 19, 2025

US 30	42,660.8	-345.4	-0.80%
US 500	5,784.9	-57.6	-0.99%
Dow Jones	43,006.59	+485.60	+1.14%
S&P 500	5,842.63	+64.48	+1.12%
Nasdaq	18,552.73	+267.57	+1.46%
S&P 500 VIX	23.40	+1.47	+6.70%
Dollar Index	104.070	-0.182	-0.17%

Crude Oil WTI	66.60	+0.29	+0.44%
Brent Oil	69.54	+0.24	+0.35%
Natural Gas	4.390	-0.060	-1.35%
Gold	2,901.71	-24.29	-0.83%
Silver	32.915	-0.219	-0.66%
Copper	4.7405	-0.0535	-1.12%
US Soybeans	1,020.13	+8.13	+0.80%

U.S. 10Y	4.305	+0.038	+0.89%
U.S. 30Y	4.596	+0.037	+0.81%
U.S. 5Y	4.087	+0.029	+0.71%
U.S. 3M	4.324	+0.010	+0.23%
US 10Y T-Note	110.59	-0.25	-0.23%
Euro Bund	127.42	-0.43	-0.34%
10-2 Yield Spread	27.17	+1.56	+6.09%

Apple	235.74	-0.19	-0.08%
NVIDIA	117.30	+1.31	+1.13%
Alphabet A	173.02	+2.10	+1.23%
Tesla	279.10	+7.06	+2.60%
Amazon.com	208.36	+4.56	+2.24%
Netflix	990.92	+18.34	+1.89%
Meta Platforms	656.47	+16.47	+2.57%

Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod In EU

Related Articles